Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, we are in good shape |
| Together, I'm confident that we will leverage this technology to maintain Casterra's competitive edge and achieve on parallel success in the global market |
| This expanding collaboration momentum validate the value of Evogene AI tech engines, MicroBoost AI, ChemPass AI and GeneRator AI, relying on our CPB platform, which we have been developing for over a decade |
| These two collaborations strengthened AgPlenu's financial position and overall perception in the agriculture market |
| These efforts not only validate our contribution, but also strengthen our financial position through non-dilutive funding and revenue streams from upfront payments, R&D fees, milestones and direct product sales |
| Another impressive and important announcement was the milestone achievement in the ongoing collaboration with Corteva for the development of novel herbicides |
| Lavie Bio's first bio-inoculant Yalos achieved several impressive milestones |
| Our recently signed agreements with seed producers in Africa and Brazil, strengthened our supply chain and market strategic change towards diversifying our production sources |
| We changed the tool manufacturer, and we are very happy with this performance and the quality of the product |
| I believe Evogene's innovative AI technology will play a crucial role in shaping the future of castor seeds, solidifying Casterra's position as a world leader in the field |
| These two collaborations strengthen Lavie Bio's financial position and overall perception in the agriculture market |
| Overall, Yalos made significant strides in regulatory approval, product expansion and distribution partnerships, positioning it as a valuable tool for enhancing productions and addressing environmental challenges in the agriculture industry |
| Dan Jacob Gelvan as AgPlenus new CEO, that's extensive experience and proven track record well positioned him to guide AgPlenus through its next phase of growth and innovation |
| These results demonstrate the efficacy of Biomica's live bacterial consortia, BMC426 and BMC427 alleviating visceral pain, a major symptom of IBS, presenting promising new treatment avenues |
| Looking forward to 2024, we expect that to see continued growth and additional collaborations benefiting from Evogene 3 AI tech engines |
| As we face the challenges ahead, and feel with optimism, driven by the great potential we see in Casterra |
| When will we definitively know that the new group of Brazilian and Kenyan farmers have been able to successfully grow and deliver the seed so we can consummate sales? Ofer Haviv So first, one of the reasons that we are growing in different regions is to be able to capture more than one season to grow castor |
| AgPlenus is looking towards an exciting year with new management in place, the collaborative agreements signed with Bayer in February and the maximum reach in the Corteva collaboration in March |
| But we are excited to see the current progress in all fronts with respect to our activities in our subsidiaries |
| No doubt, 2023 was an exciting year for the Evogene Group filled with achievements |
| Yoash brings a wealth of experience in global ad projects, and I'm confident in his ability to propel the Company forward |
| The value proposition of our AI-driven tech engines stems from the efficient finding of the needle in the haystack; therefore, increasing the probability of the success within a competitive timeframe and in a cost-efficient manner |
| We ended 2023 with a solid cash balance of approximately $31.1 million and are expecting additional cash injections from collaborations and product sales |
| We expect to see continued growth in the Evogene Group revenue in 2024 |
| Biomica securing investment from Shanghai Healthcare capital and Evogene collaborating with Verb Biotics and Colors, all highlight our growing presence and impact in the life science industry |
| In January 2024, Biomica reached a significant milestone by completing Phase I trial enrollment for its microbiome-based immuno-oncology drug with preliminary results showing promising outcomes |
| So, this is a great news for AgPlenus that we achieved first milestone in the collaboration with Corteva and we are looking at to the next challenges and milestones, which we believe will achieve them |
| Ensuring a reliable and stable supply of castor seeds is crucially meeting our customers' demand while contributing positively to local economies |
| But at least from what we are doing now, I think that we'll be able to achieve this target |
| And recently, we were fortunate to see that interest materialize |
| Statement |
|---|
| Operating loss for the fourth quarter of 2023 was approximately $7.6 million in comparison to an operating loss of approximately $3.8 million in the same period in the previous year |
| But can you talk about the supply chain of Lavie Bio and -- that I know had some challenges last year |
| I believe that the main challenge is still to be able to produce the needed quantity for year 2025 |
| There is always a challenge with respect to R&D estimate |
| And if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities |
| The total consolidated burn rate is expected to decline in 2023 as well to $21 million compared to $23.1 million in 2023 |
| This decline is mainly attributable to an expected increase in revenue in 2024 and a decrease in expenses due to the decline in economic activity |
| Net loss for the fourth quarter of 2023 was approximately $7.3 million in comparison to a net loss of approximately $3.8 million in the same period in the previous year |
| And this is -- we were hesitating what information we can disclose |
| The increase in the operating loss was mainly due to the other income recorded in the fourth quarter of 2022, as mentioned above |
| Due to the challenging market conditions of the medical cannabis sector, we have recently engaged in advanced discussions relating to the potential transfer to a third party of Canonic's operations |
| More detailed information about the risk factors potentially adversely impacting our performance can be found in our reports filed with the U.S |
| Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel |
| So, if I'm making you repeat yourself, I apologize |
Please consider a small donation if you think this website provides you with relevant information